Key Points – Second-quarter revenue rose 6% to $199.9 million, driven by strong growth in JORNAY PM and the newly acquired AZSTARYS, which helped offset declines in the NUCYNTA pain franchise. – The ADHD portfolio gained momentum: JORNAY PM revenue increased 41% to $46.1…
llion, while AZSTARYS generated $12.9 million in roughly six weeks of sales. Collegium raised its partial-year AZSTARYS revenue outlook to $65 million–$75 million. – Collegium maintained 2026 revenue guidance of $825 million–$855 million and adjusted EBITDA guidance of $445 million–$470 million, while reporting $113.8 million in adjusted EBITDA and ending the quarter with $129.5 million in cash and marketable securities after funding the AZSTARYS acquisition. – 5 Hot Stocks With Summer Buybacks You Can Cash In On Collegium Pharmaceutical (NASDAQ:COLL) reported second-quarter 2026 net product revenue of $199.9 million, up 6% from a year earlier, as growth in its ADHD franchise and BELBUCA helped offset lower revenue from the NUCYNTA pain franchise
President and Chief Executive Officer Vikram Karnani said the company’s ADHD business made significant progress during the quarter, including continued growth for JORNAY PM and the May acquisition of AZSTARYS. Collegium has completed AZSTARYS integration and sales-force training ahead of the back-to-school season, he said. “We have a diversified portfolio of six differentiated medicines, a growing ADHD franchise, and an established pain business that together provide a strong foundation for long-term value creation,” Karnani said. ADHD Portfolio Expands With AZSTARYS JORNAY PM generated $46.1 million in second-quarter net revenue, a 41% increase from the prior-year period.
Prescriptions rose 13.1% year over year, while the number of healthcare providers writing prescriptions exceeded 30,000, up 17.6%. Collegium said its share of the branded long-acting methylphenidate market reached 29.2%, an increase of 5.8 percentage points from a year earlier….